P
8.22
-0.01 (-0.12%)
| Previous Close | 8.23 |
| Open | 8.05 |
| Volume | 712,911 |
| Avg. Volume (3M) | 972,514 |
| Market Cap | 728,925,504 |
| Price / Sales | 6.53 |
| Price / Book | 3.15 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -98.10% |
| Operating Margin (TTM) | -85.88% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Total Debt/Equity (MRQ) | 21.81% |
| Current Ratio (MRQ) | 6.91 |
| Operating Cash Flow (TTM) | -42.70 M |
| Levered Free Cash Flow (TTM) | -23.09 M |
| Return on Assets (TTM) | -17.90% |
| Return on Equity (TTM) | -51.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Personalis, Inc. | Bullish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.49% |
| % Held by Institutions | 46.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blue Water Life Science Advisors, Lp | 30 Jun 2025 | 1,676,300 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (BTIG, 33.82%) | Buy |
| Median | 9.75 (18.61%) | |
| Low | 8.50 (HC Wainwright & Co., 3.41%) | Buy |
| Average | 9.75 (18.61%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 22 Oct 2025 | 11.00 (33.82%) | Buy | 8.93 |
| HC Wainwright & Co. | 08 Sep 2025 | 8.50 (3.41%) | Buy | 5.32 |
| 06 Aug 2025 | 8.50 (3.41%) | Buy | 4.41 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Oct 2025 | Announcement | Personalis to Announce Third Quarter 2025 Financial Results |
| 16 Oct 2025 | Announcement | Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing |
| 15 Sep 2025 | Announcement | Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 10 Sep 2025 | Announcement | CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test |
| 03 Sep 2025 | Announcement | Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing |
| 27 Aug 2025 | Announcement | Personalis to Participate in Upcoming Investor Conferences |
| 05 Aug 2025 | Announcement | Personalis Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |